- Motley Fool•17 hours ago
These two biopharmaceutical stocks have been going in opposite directions, which has left one trading at a bargain valuation.
- Barrons.com•19 hours ago
Gilead Sciences (GILD) has been trending lower ever since the market realized that its hepatitis-C sales were only going to keep declining for a while. Gilead's dominant HIV program, which has fallen under a cloud, probably won't do it, leading some investors to conclude there's little hope for the biotech giant without a good healthy dose of M&A. Still, it's not given much credit for its pipeline. Amsterdam, the Netherlands), we have seen data and heard feedback from KOLs that further supports our view that GILD has both the greatest breadth of pipeline assets, deep knowledge of liver biology and comprehensive biomarker strategy for treatment of Non-Alcoholic Steatohepatitis (NASH), a growing disease area affecting est.
- Zacks•20 hours ago
Results from Johnson and Johnson could be a warning sign for other drug makers, which are scheduled to report this week and the next.
GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance
Gilead Sciences, Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||66.31 x 200|
|Ask||66.50 x 800|
|Day's Range||65.71 - 66.49|
|52 Week Range||65.38 - 103.10|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||6.66|
|Dividend & Yield||2.08 (3.12%)|
|1y Target Est||N/A|